Context.-Current clinicopathologic assessment of malignant neoplastic diseases entails the analysis of specific genetic alterations that provide diagnostic, prognostic, or therapy-determining information.
c.1799T.A (p.V600E) at 0.5% mutant allele in 20 ng of genomic DNA. Precision studies with multiple operators and instruments showed very high repeatability and reproducibility with 100% (98.7%-100%) qualitative agreement among 292 individual measures in 38 runs. Evaluation of 1549 representative pathologic specimens in 2 laboratories relative to independent reference methods resulted in 99.0% (97.6%-99.6%) agreement for colorectal FFPE tissues (n ¼ 416) and 98.9% (98.2%-99.4%) for thyroid fine-needle aspiration specimens (n ¼ 1133) with an overall diagnostic odds ratio of 10 856 (2451-48 078).
Conclusions.-The multiplex assay system is a sensitive and reliable method to detect BRAF c.1799T.A mutation in colorectal and thyroid lesions. This optimized technology platform is suitable for the rapid analysis of clinically actionable genetic alterations in cytologic and histologic specimens.
(Arch Pathol Lab Med. doi: 10.5858/arpa.2013-0002-OA) W ith the advent of personalized medicine, molecular testing plays a growing role in clinical oncology and clinical pathology practices. In many cases, the analysis of specific genetic alterations complements the cytopathologic or histopathologic evaluation of solid tumor specimens and provides additional valuable information to ascertain diagnosis or predict outcome and select optimal therapeutic options. For example, treatment of non-small cell lung cancer with tyrosine kinase inhibitors targeting the epidermal growth factor receptor (EGFR) requires previous knowledge of mutations associated with drug sensitivity or resistance. 1 In metastatic colorectal cancer (mCRC), the use of anti-EGFR monoclonal antibodies is restricted to patients with tumors wild type for KRAS in codons 12 and 13. 2, 3 Other mutations in genes downstream of the EGFR signaling pathway, such as BRAF codon 600, are further associated with poor outcome and increased mortality in mCRC. 4, 5 The mutated and activated BRAF kinase (p.V600E) is also a druggable target and a specific inhibitor is now approved in Europe and the United States for use in firstline treatment of patients with metastatic melanoma. 6, 7 In thyroid cancer, testing for BRAF, KRAS, HRAS, and NRAS mutations, as well as chromosomal rearrangements involving the RET or PAX8 proto-oncogenes, increasingly contributes to the optimal surgical management of papillary thyroid carcinoma. 8, 9 Several technologies attuned to the clinical laboratory workflow and instrumentation have been developed over the years to achieve sensitive and specific detection of various clinically actionable genetic alterations. Most of these assays rely on end-point polymerase chain reaction (PCR) followed by Sanger sequencing, pyrosequencing, or amplicon detection by sizing or probe-hybridization tech-niques. 10, 11 Another common method is to perform simultaneous amplification and fluorescence detection by using real-time PCR instruments and a variety of chemistries such as intercalating dyes, hydrolysis probes, or self-probing amplicons.
12-14 Because the multiplexing capability and throughput of these technologies are somewhat limited, alternative methods capable of detecting several mutations from distinct genes have also been developed. For example, multiplex primer extension reactions followed by capillary electrophoresis sizing (SNaPshot, Life Technologies, Carlsbad, California) have been successfully implemented in the clinical setting. 15, 16 Likewise, solution hybridization of multiple PCR products on addressable microspheres, followed by flow cytometry fluorescence analysis, is broadly used in clinical diagnostic applications for bacterial, viral, genetic, or oncology targets. [17] [18] [19] [20] [21] Regardless of the technology platform, molecular methods currently in clinical use have been optimized to be compatible with anatomic pathology specimens. Because of the breadth of specimen types and preanalytic parameters commonly encountered in the clinical setting, the quantity or quality of nucleic acids recovered from these specimens can vary greatly. For the preoperative molecular assessment of papillary thyroid carcinoma, specimens are in general fine-needle aspirates (FNAs) from suspicious nodules with an indeterminate cytologic diagnosis. 8, 9 Depending on the cellularity and conditions of collection, storage, and extraction, the yield or integrity of the resulting purified genomic DNA (gDNA) can be severely compromised. For colorectal cancer, mutational analysis is performed on postsurgical formalin-fixed, paraffin-embedded (FFPE) tissues after histologic diagnosis. 2, 3, [10] [11] [12] The quality of gDNA extracted from these specimens can be dramatically affected by intramolecular and intermolecular cross-links and chemical modifications resulting in DNA fragmentation and sequence alteration. 15, 22 Preliminary studies have shown that distinct KRAS mutations can be detected by multiplex PCR and liquid bead array flow cytometry. 17 The goals of the present study were to expand the technology to relevant genetic alterations in BRAF and other genes in the EGFR pathway, to perform a complete analytic validation of the assay system, and to evaluate its performance with a large number of representative cytopathologic and histopathologic specimens.
MATERIALS AND METHODS

Clinical Specimens
All human specimens in this study were residual, deidentified gDNA samples for research purpose. No results were reported to physicians or patients or used for treatment decision and no protected health information or other information identifying patients was released. At both study sites, 10-to 20-lm-thick sections from FFPE mCRC specimens were macrodissected to selectively exclude nonmalignant, stromal, and contaminating inflammatory cells and obtain a minimum of 40% tumor content. Genomic DNA was then extracted from the tumor-enriched specimens by using laboratory-developed methods based on the RecoverAll Total Nucleic Acid Isolation Kit for FFPE Tissues (Life Technologies, Carlsbad, California) at both sites. Genomic DNA from thyroid nodules was prepared at site 2 by using a laboratorydeveloped method based on the mirVana PARIS Kit (Life Technologies) and single-pass FNAs collected and stored in RNARetain, a single-use vial containing a nontoxic solution for the preservation and stabilization of intracellular nucleic acids (Asuragen, Austin, Texas). All human gDNA samples were quantified by using a GeneQuant pro (GE Healthcare Biosciences, Pittsburg, Pennsylvania) at site 1 or a NanoDrop ND1000 (NanoDrop Technologies, Waltham, Massachusetts) at site 2.
Plasmids, Cell Lines, and Dilution Samples
Plasmid DNA carrying specific mutations were prepared at site 2 by using the QIAprep Spin Miniprep Kit (Qiagen, Hilden, Germany) and characterized by bidirectional sequencing with the Sanger method. Genomic DNA from fresh cultured cell lines was prepared at site 2 by using the QIAamp DNA Mini Kit (Qiagen), and the presence of specific genetic alterations was verified by Sanger sequencing. The following amino acid changes were confirmed: BRAF p.V600E (HT29), EGFR p.L858R/p.T790M (H1975), EGFR p.E746_A750del (H1650), EGFR p.T790M/ p.E746_A750del (H820), KRAS p.G12A (SW1116), KRAS p.G12D (PL45), KRAS p.G12V (SW480), KRAS p.G13D (HCT116), HRAS p.G12V (T24), NRAS p.Q61K (HT1080), and NRAS p.Q61R (SKMEL2). Samples for analytic characterization experiments were prepared at site 2 by serial dilution based on the nucleic acid concentration as determined by NanoDrop ND1000 (NanoDrop Technologies) for each sample. Samples positive for a given mutation (plasmid, cell line, thyroid FNA, or mCRC FFPE) were diluted in a background of purified gDNA from a cell line confirmed negative for that specific mutation, keeping the total concentration of gDNA constant. Allele copy numbers in gDNA samples were estimated by using a rounded value of 3.3 pg for the mass of a haploid human genome, corresponding to about 300 allele copies per ng of gDNA.
Molecular Assays
DNA specimens were tested with the Signature BRAF Mutations Kit (for research use only; Asuragen) or prototype assays, following the protocol described in Laosinchai-Wolf et al. 17 Briefly, DNA samples were first amplified by multiplex PCR using gene-specific biotin-modified primers. Biotinylated amplified products were then directly hybridized to mutation-specific capture probes covalently conjugated to carboxylated microspheres. Following addition of fluorescent reporter, the probe-bound PCR products were detected by flow cytometry on a Luminex 200 system (Luminex, Austin, Texas). Fluorescence signals were calculated by using a minimum of 50 beads for each target. Primers and probe sequences were according to the Catalog of Somatic Mutations in Cancer Web site (www.sanger.ac.uk/genetics/CGP/cosmic, accessed November 16, 2012) . Polymerase chain reaction amplifications and hybridization reactions were performed on a GeneAmp PCR System 9700 or a Veriti 96-Well Thermal Cycler (Life Technologies). The reference method at site 1 was the PCR/SNaPshot assay described in Lamy et al. 15 Amplifications were performed by using 100 to 1000 ng of gDNA and followed by primer extension reactions using sense or antisense SNaPshot primers and the ABI PRISM SNaPshot Multiplex Kit (Life Technologies). The purified labeled products were resolved on an ABI PRISM 3130xl Genetic Analyzer (Life Technologies) and analyzed by using GeneMapper Software version 4.0 (Life Technologies). The reference method at site 2 was a laboratory-developed real-time PCR assay using the primers and hydrolysis probes described in Smyth et al. 23 Amplifications were performed with 10 ng of gDNA on a 7500 Real-Time PCR System (Life Technologies).
Data Analysis
Percentage agreements were calculated by using qualitative assay results (positive or negative) before discrepancy analysis. Quantitative analyses of signals were performed in Excel 2010 (Microsoft Corp, Redmond, Washington). Analysis of the positive and negative signal distributions at site 1 was performed by using the retest results for the 3 samples initially discrepant. Limit of blank (LOB) values were calculated according to current guidelines (mean plus 1.645 times the standard deviation), assuming 1-sided normal-like distribution of negative signals. 24 Confidence intervals were calculated by using the Wilson score interval for percentage agreements or the method described by Armitage and Berry for diagnostic odds ratios.
25-27
RESULTS
Assay Workflow
The qualitative assay system consisted of 3 steps: (1) multiplex PCR amplification on purified gDNA, (2) hybridization of PCR products onto probes conjugated to spectrally distinct beads, and (3) simultaneous bead sorting and fluorescence analysis by flow cytometry (Figure 1 ). For 48 reactions in a 96-well plate format, the total assay time was less than 4 hours with approximately 1 hour of labor time and 3 hours of instrument time. The subsequent data analysis step was straightforward with qualitative interpretation of the median fluorescence intensity (MFI) signals reported for each target-specific bead population relative to a single positive/negative cutoff value (500 MFI). Representative examples of assay output, including amplification and detection of an endogenous control sequence and 3 plate/ run controls, are presented in Table 1 .
Qualitative Analysis of Distinct Gene Mutations
Evaluation of the BRAF assay with 20 ng of gDNA extracted from well-characterized cell lines or 6000 copies of plasmids spiked into 20 ng of gDNA from the BRAF mutation-negative cell line DU145 showed specific detection of the mutation c.1799T.A (p.V600E) with a high signal-to-noise ratio (Table 1) . With the same multiplex technology and workflow, mutational analysis of BRAF codon 600 was effectively combined with the detection of 12 distinct mutations in KRAS codons 12 and 13 (Supplemental Tables 1 through 3 ; supplemental digital content). No crossdetection was observed between BRAF and 7 KRAS mutations in codons 12/13 or 5 additional rare mutations in KRAS codon 13. Similarly, 6 distinct mutations in HRAS codons 12/61 or NRAS codon 61 could be detected in a single-well assay (Supplemental Table 4 ; see supplemental digital content at www.archivesofpathology.org). In addition to single-nucleotide substitutions, other types of genetic abnormalities, such as deletions in EGFR exon 19, could be assessed in the same reaction (Supplemental Table 5 ; see supplemental digital content at www.archivesofpathology. org). The presence of multiple genetic alterations in a given test sample, for example EGFR p.T790M plus p.L858R or p.T790M plus p.E746_A750del, did not interfere with the assay. Overall, multiplex assays for 22 relevant mutations in the BRAF, HRAS, KRAS, NRAS, or EGFR genes were successfully established (Table 2 ). To fully characterize the technology platform, extensive validation studies were next performed with the prototypic BRAF assay.
Normal Range and LOB
The range of MFI signals in well-characterized, true negative samples was determined by repetitively testing 5 sample types (Table 3) . A no-DNA template control and a plasmid DNA containing no BRAF-related sequences were tested in triplicate in 15 runs and BRAF-negative cell line, thyroid nodule FNAs, and mCRC FFPE tissue samples were tested in triplicate in 9 runs. The distributions of negative signals generated by the BRAF c.1799T.A probe across 171 independent measures were similar in the absence or presence of gDNA (Table 3 ). Analysis at the sample level also showed similar performance for different sample types (Figure 2 ). Mean signals (73 to 88 MFI), standard deviations (35 to 47 MFI), and maximum signals (170 to 259 MFI) were all in the same range. The calculated LOB values, representing 95% of the signal distribution for each sample type, were at least 3-fold lower than the 500 MFI cutoff value (33 LOB ¼ 421 to 492 MFI and 447 MFI overall; Figure  2 ). These data indicate that a false-positive qualitative result (c.1799T.A probe signal .500 MFI) is not expected in true negative samples (P , .001).
Analytic Sensitivity and Specificity
To confirm the analytic specificity of the BRAF assay and determine its limit of detection (LOD) relative to the 500 MFI cutoff, serial dilutions of gDNA extracted from c.1799T.A-positive cultured cell line (HT29), thyroid nodule FNA, or mCRC FFPE tissue were tested (Figure 3,  A) . The LOD was between 0.1% and 1% dilution at 20-ng gDNA input for all sample types. Additional mapping experiments suggested a LOD between 0.4% and 0.8% dilution (Supplemental Table 6 ; see supplemental digital content at www.archivesofpathology.org) and repeated testing with independent dilutions of HT29 gDNA showed reproducible detection at 0.5% dilution (Figure 3, B) . Coamplification of BRAF and KRAS in a single reaction format resulted in a minimal decrease in c.1799T.A probe signal and a LOD of 1% (Supplemental Figure 1 ; see supplemental digital content at www.archivesofpathology. org). To further investigate analytic specificity, a series of plasmids carrying individual mutations were tested in multiple runs (Supplemental Table 7 Table 8 ; see supplemental digital content at www.archivesofpathology.org).
Method Precision
In the analytic experiments described above, all replicates across all runs generated the same qualitative positive/ negative results. To fully validate the method precision, 8 additional studies were performed with the BRAF assay ( Table 4) . Within-run precision (repeatability) was evaluated by testing 4 medium to low positive samples (20%, 10%, 4%, and 2% HT29 dilutions) in quadruplicate and 2 low positive samples (2% and 1% HT29 dilutions) in 12 replicates (n ¼ 40). Between-run precision (reproducibility) was evaluated by testing the positive, negative, and no-DNA template controls provided with the kit in 26 runs with 3 different operators (n ¼ 78). Total precision (withinlaboratory precision) was further evaluated by testing (1) high, medium, and low positive samples (100%, 20%, and 2% HT29 dilutions) and 1 negative sample (DU145) in triplicate in 5 runs with 3 operators (n ¼ 60), (2) six thyroid nodule FNAs or mCRC FFPE samples (3 positive and 3 negative) in triplicate in 3 runs with the same operator (n ¼ 54), and (3) five thyroid nodule FNAs or mCRC FFPE samples (3 positive and 2 negative) in quadruplicate in 3 runs with 3 operators (n ¼ 60). There was 100% qualitative agreement between all replicates and all runs for a total of 292 individual measures (95% confidence intervals: 98.7%-100%) (Table 4) . A precision of 100% (97.9%-100%) was also observed for the hybridization step only by performing 3 independent hybridizations on the same day with 2 instruments and 7 samples amplified in quadruplicate (n ¼ 84) and 4 independent hybridizations on 4 different days on the same instrument with 8 samples amplified in triplicate (n ¼ 96) (Table 4) .
Compatibility With Pathologic Specimens
To assess the multiplex technology with different tissue types, specimen processing methods, and testing sites, the similar distribution of negative signals across samples and sites (Figure 4, B) . The median positive signals were consistent with the differences in specimen types and gDNA inputs (11.25 ng at site 1; 20 ng at site 2). Overall, 95% of the positive signals were at least 3-fold above the cutoff (.1533 MFI) and 95% of the negative signals were at least 3-fold below the cutoff (,159 MFI). These data confirmed the high signal-to-noise ratio of the technology regardless of the potential preanalytic differences between sites or sample types.
Agreement With Reference Methods
The qualitative positive/negative BRAF assay results were also compared against independent molecular data obtained with reference methods based on multiplex PCR/SNaPshot technology at site 1 or real-time quantitative PCR technology at site 2 (Table 5 ). For mCRC FFPE specimens, the overall agreement between methods was 99.0% (412 of 416). Testing at site 1 initially resulted in 2 false-negative results with c.1799T.A signals just below the cutoff (431 and 344 MFI) and 1 false-positive result with a low mutant signal (744 MFI). The 3 discrepancies were resolved after retesting (data not shown). At site 2, one apparent falsepositive result was observed (1193 MFI) and could not be ruled out after retesting. For thyroid nodule FNA specimens, the overall agreement between methods was 98.9% (1121 of 1133) (Table 5 ). Twelve apparent false positives were observed and were all confirmed positive after retesting (data not shown). Overall, the positive and negative agreements for the combined 1549 specimens were 99.2% (234 of 236) and 98.9% (1299 of 1313), respectively, with a corresponding diagnostic odds ratio of 10 856 (Table 5) .
COMMENT Molecular methods designed to complement the cytopathologic or histopathologic evaluation of solid tumor lesions should be compatible with anatomic pathology specimens. In the present study, the BRAF assay was validated relative to established reference molecular methods 15, 23 by using 1549 residual gDNA samples extracted from representative thyroid nodule FNAs or mCRC FFPE tissues. The positive, negative, and overall agreements were all greater than 97.7% with lower bound confidence intervals greater than 92.1% in both the cytologic and histologic sample sets. The 12 apparent false-positive results observed with thyroid nodule FNA samples likely reflected the difference in analytic sensitivity between the 2 assays at site 2 (0.5% for the BRAF assay, approximately 5% for the reference method). Retesting of these samples and more than 90% of the true-positive samples for which enough residual gDNA was available (n ¼ 134) ruled out a potential technical error or cross-contamination issue. Overall, calculation of the diagnostic odds ratio for the combined 1549 specimens showed an excellent assay performance with a lower bound confidence interval greater than 2451. This metric is a single global indicator of assay performance and measures the effectiveness of a test to predict a disease independently of its prevalence. 27 In our study, it can further be interpreted as the odds of a true-positive BRAF assay result (234 of 2) being 10 856 times higher than the odds of a false-positive result (14 of 1299).
For routine use in clinical pathology laboratories, novel molecular methods should also be compatible with the clinical laboratory workflow and demonstrate robust and reliable performance. Comprehensive analytic characteriza- Run  1  1  26  5  3  3  3  4  Sample  4  2  3  4  6  5  7  8  Replicate  4  12  1  3  3  4  4  3  Measure  16  24  78  60  54  60  84  96  Operator  1  1  3  3  1  3  1  1  Instrument  1  1  2  2  1  1  2  1  Agreement, %  100  100  100  100  100  100  100  100 Abbreviation: PCR, polymerase chain reaction. Specificity for the BRAF mutation c.1799T.A was confirmed with cell lines and residual clinical specimens, and potentially interfering mutations were evaluated with synthetic plasmids. The observed cross-detection with plasmids c.1799_1800delinsAT (p.V600D), c.1799_1800de-linsAA (p.V600E2), and c.1798_1799delinsAA (p.V600K) was not surprising since these double-nucleotide substitutions result in a T to A change at position 1799 such as for p.V600E (c.1799T.A). Previous studies 13, 29 have shown that p.V600D, E2, and K can also be sporadically detected by real-time PCR assays designed to detect BRAF p.V600E in melanoma specimens. These double mutations are relatively frequent in melanoma but could not be evaluated with representative clinical specimens in our study owing to their scarcity in colorectal and thyroid lesions. Specificity for distinct genes or distinct amplified regions within the same gene was however confirmed with the prototype BRAF/ KRAS, HRAS/NRAS, and EGFR assays. Our results indicate that a single technology platform can be used for the qualitative analysis of mutations in BRAF codon 600, HRAS codons 12/61, KRAS codons 12/13, NRAS codon 61, or EGFR codons 790/858, as well as deletions in EGFR exon 19. Each assay was performed in less than 4.5 hours in a 96-well plate format with a very favorable signal-to-noise ratio, enabling a simple and safe data interpretation relative to a single qualitative cutoff. Evaluation of serial dilutions with plasmid and cell line samples further suggested a similar LOD of at least 1% or 60 copies of mutant allele for HRAS, KRAS, NRAS, and EGFR (data not shown).
Multiplex assay systems provide obvious operational advantages relative to repeated series of individual PCR. In principle, all 22 mutations evaluated here could be further combined in a single assay. However, such a large panel would be extremely difficult to validate for every mutation and pathologic specimen type. Subpanels focusing on specific genes may be more practical, address most clinical needs for different tissue/specimen types, and prevent unnecessary testing. In addition, one advantage of the Luminex flow cytometer is the possibility to simultaneously analyze the fluorescence output from different assays using the multibatch mode. For example, the KRAS and BRAF assays can be performed in the same run to assess up to 45 mCRC FFPE specimens in a single 96-well plate, and up to 30 thyroid FNA specimens can be tested for BRAF, KRAS, and NRAS/HRAS in a single plate without significantly affecting the workflow or total assay time (data not shown).
Testing for oncogenic gene rearrangements in cytologic thyroid specimens also plays a key role in the management of patients with thyroid cancer to guide appropriate surgical therapy. 8, 9 Independently from the present work, the multiplex assay system has been further optimized to detect fusion transcripts resulting from chromosomal inversions or translocations such as RET-PTC and PAX8-PPARG in thyroid nodule FNA specimens (unpublished results). In addition, preliminary studies suggest that the assays are compatible with histologic FFPE thyroid specimens as well as melanoma, lymph node, and lung tissues (unpublished results). We conclude that the multiplex assay system described here is a general technology platform suitable for the rapid analysis of relevant and clinically actionable genetic alterations in a variety of solid tumor specimens. Future validation studies for specific panels could provide additional speed and flexibility to clinical pathology laboratories and further advance the personalized molecular management of cancer patients.
